<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F0292598-9FA5-42BD-BDE2-0DFCB063CD16"><gtr:id>F0292598-9FA5-42BD-BDE2-0DFCB063CD16</gtr:id><gtr:name>European Network for the Study of Adrenal Tumours (ENS@T)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A7140509-4007-4144-9EDD-47F15BB76757"><gtr:id>A7140509-4007-4144-9EDD-47F15BB76757</gtr:id><gtr:name>ENSAT-HT</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F0292598-9FA5-42BD-BDE2-0DFCB063CD16"><gtr:id>F0292598-9FA5-42BD-BDE2-0DFCB063CD16</gtr:id><gtr:name>European Network for the Study of Adrenal Tumours (ENS@T)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A7140509-4007-4144-9EDD-47F15BB76757"><gtr:id>A7140509-4007-4144-9EDD-47F15BB76757</gtr:id><gtr:name>ENSAT-HT</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/90300D17-7BE0-4E54-B57F-4F4569547B87"><gtr:id>90300D17-7BE0-4E54-B57F-4F4569547B87</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/76352B57-0623-44D3-B54F-9A7A3AF470B3"><gtr:id>76352B57-0623-44D3-B54F-9A7A3AF470B3</gtr:id><gtr:firstName>Wiebke</gtr:firstName><gtr:surname>Arlt</gtr:surname><gtr:orcidId>0000-0001-5106-9719</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801473"><gtr:id>F5852C30-44C8-40DE-B6A0-C6727F07E4F6</gtr:id><gtr:title>Steroid profiling as a biomarker tool in the diagnosis and monitoring of adrenal tumours</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801473</gtr:grantReference><gtr:abstractText>Adrenal tumours are common, affecting 1-2% of the general population. However, these tumours become more common with ageing and 3% of 40-year-olds and 10% of 70-year-olds have an adrenal tumour, many of them without knowing it. The majority of adrenal tumours are discovered incidentally, mostly following an imaging procedure like CT scanning arranged for other reasons than suspected adrenal disease. Once discovered, nodules in the adrenal need to be carefully evaluated as they may overproduce hormones with a potentially detrimental effect on health and, importantly, they could be malignant, either arising from the adrenal itself or representing metastases of other malignancies. Currently we use different imaging procedures and blood tests in the work-up of patients with adrenal tumours, but this is not always informative enough and it is often difficult to decide whether an adrenal tumour is benign or malignant. We have developed a biomarker tool that measures the excretion of steroid hormones deriving from the adrenal gland in urine samples provided by adrenal tumour patients. Preliminary results indicate that there are highly significant differences in steroid hormone excretion between benign and malignant adrenal tumours. In this proposal we will validate this method by the prospective analysis of a large number of urine samples from adrenal tumour patients by our measurement technique, called gas chromatography/mass spectrometry (GC/MS). Measurement results will be analyzed in collaboration with mathematicians who will help us to identify those hormones that will inform us best about the differences between benign and malignant tumours. Use of a related technology method - liquid chromatography/ mass spectrometry, LC/MS/MS ? will then be employed for the rapid measurement of steroids, which will help to integrate our biomarker tool into routine clinical practice. Patient recruitment to this study will be driven by national and international collaborative networks including the European Network for the Study of Adrenal Tumours (ENS@T), which will ensure that we can recruit the necessary patient number during the study lifetime. This proposal links a team of experienced researchers from different disciplines, which will ensure that we succeed in improving the care of patients with adrenal tumours.</gtr:abstractText><gtr:technicalSummary>Adrenal tumours are common, with a prevalence of 1-2% in the general population. Prevalence increases with age, with 3% of 40-year-olds and 10% of 70-year-olds harbouring an adrenal tumour. In an ageing society and with the increasingly widespread use of abdominal imaging the number of incidentally discovered adrenal tumours is rapidly increasing and represents a huge burden for the health system. Diagnostic work-up of adrenal incidentalomas aims to exclude malignancy and steroid excess, but is currently compromised by a lack of sensitive diagnostic tools. This shortcoming is addressed by this proposal that aims to establish steroid profiling as a biomarker tool in the differential diagnosis of adrenal incidentaloma. Feasibility studies analysing urinary steroid metabolite excretion in 83 benign and 35 malignant adrenal tumours by gas chromatography/mass spectrometry indicate significant differences in steroid excretion, with high androgen and glucocorticoid precursors in malignant tumours. Preliminary analysis indicates a high diagnostic sensitivity and specificity of a distinct subset of steroid metabolites. Based on these data we plan to analyse 24-h urinary steroid excretion in a large cohort of adrenal incidentaloma patients (n=1000) to prospectively evaluate the diagnostic value of this novel biomarker tool. In an important transfer step to implementation of the biomarker tool in routine clinical practice, we will establish liquid chromatography/tandem mass spectrometry (LC/MS/MS) for rapid high throughput measurement of steroid markers identified as most differentiating by biocomputational analysis. The latter will apply machine learning techniques, taking two different but complementary approaches, prototype-based relevance learning and probabilistic Bayesian kernel models. These methods will be utilised to identify discriminative steroids, determine their prognostic and predictive value and develop generative models that could also give mechanistic insights. Recruitment to the study will be facilitated by local, national and international networks including the European Network for the Study of Adrenal Tumours (ENS@T), which already contributed 500 urine samples in 12 months, facilitating preliminary analysis. Clinical data will be stored in a common database format that has been developed, agreed and implemented by ENS@T and that will be made available to all participating centres of the UK Adrenocortical Tumour Network (UK ACT). This proposal links an extensive team of researchers and research facilities across the UK and Europe, generating a unique, interdisciplinary expertise that will ensure the success of this project; results will improve the diagnostic management of a common condition.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>727149</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>ENSAT-HT</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>ENSAT-HT</gtr:description><gtr:id>C86E2A49-F35C-4B79-85DC-8DB8DD0BF9FB</gtr:id><gtr:impact>H2020 funding</gtr:impact><gtr:outcomeId>58b9abacf22b42.64704361-1</gtr:outcomeId><gtr:partnerContribution>pan-european consortium with multi-disciplinary expertise</gtr:partnerContribution><gtr:piContribution>European collaboration on analysis of integrated comics in patients with adrenal tumours and hypertension</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Network for the Study of Adrenal Tumours (ENS@T)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>ACC-PROTECT</gtr:description><gtr:id>0CCB7482-301A-4F4A-95A0-56D362510C6A</gtr:id><gtr:impact>This is a prospective test validation trial.</gtr:impact><gtr:outcomeId>56e11f6fa61838.01723553-2</gtr:outcomeId><gtr:partnerContribution>The partners within ENSAT have signed up to include patients and send samples</gtr:partnerContribution><gtr:piContribution>This is a Pan-European Consortium led by me that will take the ADIUVO findings forward, focussing on our highly promising preliminary findings regarding the utility of monitoring for recurrence in adrenocortical carcinoma by steroid metabolomics.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>ACC-PROTECT</gtr:description><gtr:id>5AD4998E-E969-44B9-8EFD-463C3C7616DA</gtr:id><gtr:impact>This is a prospective test validation trial.</gtr:impact><gtr:outcomeId>56e11f6fa61838.01723553-1</gtr:outcomeId><gtr:partnerContribution>The partners within ENSAT have signed up to include patients and send samples</gtr:partnerContribution><gtr:piContribution>This is a Pan-European Consortium led by me that will take the ADIUVO findings forward, focussing on our highly promising preliminary findings regarding the utility of monitoring for recurrence in adrenocortical carcinoma by steroid metabolomics.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>European Science Foundation Network</gtr:description><gtr:id>6EEC4A0B-3471-4A0E-BAA8-B38ABDB7B7FB</gtr:id><gtr:impact>multilateral collaboration and funding (2009-2014), enhancement of international collaboration, facilitation of clinical studies that underpin this grant</gtr:impact><gtr:outcomeId>HXrdv1ugQQV-1</gtr:outcomeId><gtr:partnerContribution>ongoing collaboration on active research projects</gtr:partnerContribution><gtr:piContribution>The PI is a steering committe member for the ESF research network &amp;quot;European Network for the Study of Adrenal Tumours&amp;quot;.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Medical Clinic Innenstadt</gtr:department><gtr:description>ENSAT-CANCER</gtr:description><gtr:id>BCA2B259-1659-42F2-AD57-13A5CA04CF9B</gtr:id><gtr:impact>This initiative arose from ENSAT and now has achieved successful FP7 funding for a 5-year collaborative research project that will start in January 2011 and will be synergistic with the research related to this grant</gtr:impact><gtr:outcomeId>Bq5WYdtRXAR-1</gtr:outcomeId><gtr:partnerContribution>international collaboration, recruitment to clinical studies underpinning the research funded by this grant</gtr:partnerContribution><gtr:piContribution>The PI is a steering committee member of the FP7 Collaborative Research Project &amp;quot;European Network for the Study of Adrenal Tumours - CANCER&amp;quot; that aims at improving diagnostic and therapeutic options for patients with adrenal cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient Strand for ACC Support UK Patient Group at the Annual Meeting of the European Network for the Study of Adrenal Tumours Nov 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B45DC1F9-78FC-4CFA-8C86-73AE089333E7</gtr:id><gtr:impact>60 patients with adrenocorticla carcinoma and their partners/carers attended the dedicated whole day patient strand during the Annual Scientific Meeting of the European Network for the Study of Adrenal Tumours. This was a whole day event during the 2-day scientific conference, patients had sessions geared towards patients only and were invited to attend a scientific oral session and the poster sessions focussing on adrenocortical carcinoma.</gtr:impact><gtr:outcomeId>58b980a4bded62.99315142</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.accsupport.org.uk/2016-patient-information-event-confirmed/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>307191</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ENS@T-CANCER (6m euros across 16 participants)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>55E19E7E-6F62-4B32-A583-DC2F1C82C4BF</gtr:id><gtr:outcomeId>VLaRVNQX4EH0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Research Training Fellowship</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A38B95C5-171C-4423-8A73-1B7E8323AEDC</gtr:id><gtr:outcomeId>asbJ5PLb65s</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78643</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Universitas 21 PhD Studentship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>C5E63449-C717-4BD3-BD43-E84B2B139382</gtr:id><gtr:outcomeId>eoJSGx7i9cc</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Science Foundation Research Network programme</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>European Science Foundation (ESF)</gtr:fundingOrg><gtr:id>97C19691-E94C-4B12-A9A8-05387F25A6B4</gtr:id><gtr:outcomeId>KVNw2GrQCE20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59562</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C26387/A15622</gtr:fundingRef><gtr:id>50A3A141-BC85-4CD6-BAE5-836240B20147</gtr:id><gtr:outcomeId>jMP41KQXALe</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>we discovered in the urine of mitotane-treated patients with malignant adrenal tumours that treatment with mitotane significantly reduced global 5a-reductase activity as indicated by a number of steroid substrate over product ratios and concluded that substances of similar structure will act as 5alpha-reductase inhibitors</gtr:description><gtr:grantRef>G0801473</gtr:grantRef><gtr:id>C54DA5E2-64F0-48E1-9AD4-82E2B0CCD259</gtr:id><gtr:impact>negotiations ongoing with GSK</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>p4CHVmBWe7g</gtr:outcomeId><gtr:patentId>WO2012110768</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Chlorhalogen compounds as a novel class of inhibitors of the enzyme 5alpha-reductase</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This is a novel diagnostic tool that provides highly sensitive and specific differentiation of benign from malignant adrenal tumours, a major advance in the diagnosis of adrenal incidentalomas, superior to imaging. It is highly likely that this patent will also be highly useful for other steroid-producing or steroid-dependent tumours, including differential diagnosis and treatment monitoring.</gtr:description><gtr:grantRef>G0801473</gtr:grantRef><gtr:id>0BF8E6EA-3E93-4586-BCAF-BD3B32F87073</gtr:id><gtr:impact>A new joint venture (Bioscience Ventures Ltd) has been set up by the University of Birmingham and an SME specifically for the commercial exploitation of this patent.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>cu5dbZqQKZ4</gtr:outcomeId><gtr:patentId>WO2010092363</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Steroid profiling for the diagnosis of hormone-producing and hormone-dependent tumours</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A new machine learning approach for processing steroid metabolome data.</gtr:description><gtr:grantRef>G0801473</gtr:grantRef><gtr:id>31767C4B-B37B-424C-8774-D5EE4D3E0C17</gtr:id><gtr:impact>the new approach facilitated the development of novel diagnostic biomarker approaches</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58b981914a29f5.09214521</gtr:outcomeId><gtr:patentId>GB1615330.6</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Relevance learning vector quantisation in variable dimensional spaces</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Alta Innovations/Abbingdon Health Joint venture</gtr:companyName><gtr:description>This is a new joint venture between the University of Birmingham and an SME specialising on diagnostic test development.</gtr:description><gtr:id>8B68CBB7-1A20-4A63-8474-53198F11412B</gtr:id><gtr:impact>just started business</gtr:impact><gtr:outcomeId>jmHVc12Jc6Q</gtr:outcomeId><gtr:url>http://www.abingdon-health.com/group-companies/bioscience-ventures-ltd</gtr:url><gtr:yearCompanyFormed>2010</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>5DB0845F-3CE5-4DC0-895D-7F496F7975B7</gtr:id><gtr:title>Glucocorticoids and 11?-HSD1 are major regulators of intramyocellular protein metabolism.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50266dbb5bd134a51e37cc9434e56cf3"><gtr:id>50266dbb5bd134a51e37cc9434e56cf3</gtr:id><gtr:otherNames>Morgan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>5899cccb289589.72720995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42ED7B79-EF50-472F-AD16-FE917B31011D</gtr:id><gtr:title>Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75e41a1425765cfde6590fe88ff5fc06"><gtr:id>75e41a1425765cfde6590fe88ff5fc06</gtr:id><gtr:otherNames>Elbelt U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>546459d70ae827.44708339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43905AFF-DC1D-414E-A2BD-05D2D961F8A9</gtr:id><gtr:title>Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8cc7df29ffb70aa576ec1f0bc8c0873"><gtr:id>f8cc7df29ffb70aa576ec1f0bc8c0873</gtr:id><gtr:otherNames>Hern?ndez-Ram?rez LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>56e11cc8e659a5.40411446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7735FDFB-EF2C-433C-B049-F9E47724B3F9</gtr:id><gtr:title>Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5aa65bdca46562.15312864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7477E3A8-48E2-4DCE-9C26-3FF447B52D4A</gtr:id><gtr:title>Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeb7f3abb900b7f62cab77f20f48bbb"><gtr:id>fbeb7f3abb900b7f62cab77f20f48bbb</gtr:id><gtr:otherNames>Mahata B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546459d80b7770.53433733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3183E072-8AD1-4B21-872B-4220616B0E8F</gtr:id><gtr:title>Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee2bb84b8c4f4944ad2235096215513e"><gtr:id>ee2bb84b8c4f4944ad2235096215513e</gtr:id><gtr:otherNames>Sue M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>546459d6b08372.22612587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A499A0E-7F7F-4C49-B25B-27B21338D980</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d98bf3954a69fc156c27af9fb0725e"><gtr:id>88d98bf3954a69fc156c27af9fb0725e</gtr:id><gtr:otherNames>Hardy RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5899ccce1275a6.73528981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD10FAE1-821A-44A6-9DB8-2D11ADA86489</gtr:id><gtr:title>Acromegaly.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01dc0ed26132145d0eddfb05f09f7965"><gtr:id>01dc0ed26132145d0eddfb05f09f7965</gtr:id><gtr:otherNames>Dineen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>5899cc38528dc8.91468951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87B7D186-7217-451D-B5D3-96E740EFF393</gtr:id><gtr:title>Pheochromocytoma Is Characterized by&amp;nbsp;Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and&amp;nbsp;Myocardial Dysfunction.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dae2dbda8dbce0f217924cf8bbac483f"><gtr:id>dae2dbda8dbce0f217924cf8bbac483f</gtr:id><gtr:otherNames>Ferreira VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>58b927c93ced87.79164143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D1304B4-4236-48F2-B838-7863F3E50072</gtr:id><gtr:title>Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling.</gtr:title><gtr:parentPublicationTitle>Current opinion in endocrinology, diabetes, and obesity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2fa798f4e6726a0e333148051d4950"><gtr:id>4c2fa798f4e6726a0e333148051d4950</gtr:id><gtr:otherNames>Bancos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1752-296X</gtr:issn><gtr:outcomeId>58b927c788f4c2.11499999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43888D79-1C77-4825-A99D-F8E8E5D59F6D</gtr:id><gtr:title>Supine or sitting plasma metanephrine screening? A unifying solution for patients and doctors.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce88725eec3a951b0f9544cbef79dc4"><gtr:id>1ce88725eec3a951b0f9544cbef79dc4</gtr:id><gtr:otherNames>Chortis V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>546459d67de757.91956248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8641A235-B151-4555-B99A-F3A0107D853A</gtr:id><gtr:title>A detour guide to the Endocrine Society Clinical Practice Guideline on case detection, diagnosis and treatment of patients with primary aldosteronism.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>pm_12491_11_19797500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>813AF3B6-3BEB-4DD9-AB81-09B9B0A4E777</gtr:id><gtr:title>Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.</gtr:title><gtr:parentPublicationTitle>Annals of clinical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ebb4973a2230ae122115015776c3e39"><gtr:id>6ebb4973a2230ae122115015776c3e39</gtr:id><gtr:otherNames>Peitzsch M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0004-5632</gtr:issn><gtr:outcomeId>pm_12491_21_23512172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F0A6B68-94DD-4B1D-9A38-39F393083D06</gtr:id><gtr:title>Supine or sitting? Economic considerations regarding patient position during plasma metanephrine analysis for the exclusion of chromaffin tumours.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce88725eec3a951b0f9544cbef79dc4"><gtr:id>1ce88725eec3a951b0f9544cbef79dc4</gtr:id><gtr:otherNames>Chortis V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>546459d72f3828.27532839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>930460B5-7590-4BAF-84BE-5172B44EDF87</gtr:id><gtr:title>The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58bfd71fbbd42020ba6ceca87a1fcda7"><gtr:id>58bfd71fbbd42020ba6ceca87a1fcda7</gtr:id><gtr:otherNames>Shaw GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e11c5df0b904.48234589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1DDB584-57A0-4DF6-A46B-EE6B9EF60E3C</gtr:id><gtr:title>Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/015b14afa6b5b3668d14f53b709742c8"><gtr:id>015b14afa6b5b3668d14f53b709742c8</gtr:id><gtr:otherNames>Weigel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>5899ccce911dd5.94872711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>794D95D3-908B-461F-AA3C-E553B94322F8</gtr:id><gtr:title>Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76de43c015d8b0a7018fd75bd4abe10f"><gtr:id>76de43c015d8b0a7018fd75bd4abe10f</gtr:id><gtr:otherNames>Richards J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_12491_21_22411952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>630E148B-6325-4212-9595-C2705E392559</gtr:id><gtr:title>Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c7e7933f54893a2ead60368a229e39"><gtr:id>57c7e7933f54893a2ead60368a229e39</gtr:id><gtr:otherNames>Debono M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>56e11cc8869226.12836219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31DAF4C5-B8E0-4E60-ADAE-10F1C580BE13</gtr:id><gtr:title>Approach to the patient: the adult with congenital adrenal hyperplasia.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92526e54c1bb8b06b4e87f355fec401c"><gtr:id>92526e54c1bb8b06b4e87f355fec401c</gtr:id><gtr:otherNames>Auchus RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_23837188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>005532EA-D397-4317-B895-CB6D58DF1E0D</gtr:id><gtr:title>Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>544e13e944d9d1.06906757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9ABA09C-2F57-4E71-9623-7146C8D4789D</gtr:id><gtr:title>The Regulation of Steroid Action by Sulfation and Desulfation.</gtr:title><gtr:parentPublicationTitle>Endocrine reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2283f1dfd4abf59331b0a9a3939afe36"><gtr:id>2283f1dfd4abf59331b0a9a3939afe36</gtr:id><gtr:otherNames>Mueller JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0163-769X</gtr:issn><gtr:outcomeId>56e11c5ec51994.94235705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8281291-D717-40B5-86C8-41137F682B09</gtr:id><gtr:title>DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2fa798f4e6726a0e333148051d4950"><gtr:id>4c2fa798f4e6726a0e333148051d4950</gtr:id><gtr:otherNames>Bancos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>58b927c8def3e6.37941347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA4A5B40-F36B-4F6B-BB40-33F5FB92A363</gtr:id><gtr:title>MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/683f15bc84737d29fc6068129f342f9e"><gtr:id>683f15bc84737d29fc6068129f342f9e</gtr:id><gtr:otherNames>Dinnes J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>58b927c90b8313.48644929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38B80318-5C47-4704-A836-B20362442746</gtr:id><gtr:title>Male 11?-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74757ba33a4f5d12d4ab5eea50de0695"><gtr:id>74757ba33a4f5d12d4ab5eea50de0695</gtr:id><gtr:otherNames>Larner DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>5899cccc346691.00551550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F43C6872-7336-4C70-8BDB-27D7307F4575</gtr:id><gtr:title>THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2fa798f4e6726a0e333148051d4950"><gtr:id>4c2fa798f4e6726a0e333148051d4950</gtr:id><gtr:otherNames>Bancos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>58b927c81b39b9.23540610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F04A332-2878-4208-A015-FB19C978E1FC</gtr:id><gtr:title>SFRP2 Is Associated with Increased Adiposity and VEGF Expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faad224b0d9f2591b7db726f3b40c7a"><gtr:id>6faad224b0d9f2591b7db726f3b40c7a</gtr:id><gtr:otherNames>Crowley RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5899cccd4ab794.53893970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD1D13D7-2BD2-4571-BC4B-D6EDB1595C52</gtr:id><gtr:title>Fluconazole inhibits human adrenocortical steroidogenesis in vitro.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2148bc75ddac1b8cf0f66e16df48edb6"><gtr:id>2148bc75ddac1b8cf0f66e16df48edb6</gtr:id><gtr:otherNames>van der Pas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>pm_12491_21_23038793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE81BC1C-75FA-4C6B-A6BC-E0F1C0646126</gtr:id><gtr:title>Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25f3ec830f0d034469efbb20665c8c68"><gtr:id>25f3ec830f0d034469efbb20665c8c68</gtr:id><gtr:otherNames>Woods CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>56e11c5e40e0b9.15191088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>219C51C8-BFD2-4E99-95F9-3EE034B92714</gtr:id><gtr:title>Analysis of flow cytometry data by matrix relevance learning vector quantization.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5b28728b6b352594129dac77666727"><gtr:id>7d5b28728b6b352594129dac77666727</gtr:id><gtr:otherNames>Biehl M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12491_21_23527184</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FAE91ED-530A-46C9-A4C2-5333351E0C67</gtr:id><gtr:title>Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc134d38cb0ed58971297db9ce3533bc"><gtr:id>bc134d38cb0ed58971297db9ce3533bc</gtr:id><gtr:otherNames>Fassnacht M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>58b927c7e30121.80330653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4137F20A-0339-44A4-B0E8-8CA98447B7DE</gtr:id><gtr:title>Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/684e74d4e19e7c0c07ae93b4a0bfcbdc"><gtr:id>684e74d4e19e7c0c07ae93b4a0bfcbdc</gtr:id><gtr:otherNames>Puar T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>58b927c9b59d02.65419543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>938ECC42-5EE6-4283-9A1E-2A45C8AFB9E1</gtr:id><gtr:title>Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5a-reductase, explaining the need for personalized glucocorticoid and androgen replacement.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce88725eec3a951b0f9544cbef79dc4"><gtr:id>1ce88725eec3a951b0f9544cbef79dc4</gtr:id><gtr:otherNames>Chortis V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>544a37f0f2c766.90506396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F121F3E-B008-44E0-AE1F-F7E9D048162B</gtr:id><gtr:title>Combination chemotherapy in advanced adrenocortical carcinoma.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc134d38cb0ed58971297db9ce3533bc"><gtr:id>bc134d38cb0ed58971297db9ce3533bc</gtr:id><gtr:otherNames>Fassnacht M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12491_21_22551107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7A755BA-2A8F-405D-B4F5-DD2A22A61A7B</gtr:id><gtr:title>A feminizing adrenocortical carcinoma in the context of a late onset 21-hydroxylase deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44678f6b2a65a8173dc3bd0101d2f870"><gtr:id>44678f6b2a65a8173dc3bd0101d2f870</gtr:id><gtr:otherNames>Lib? R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_540e16ae16a429ae7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A55F48D5-9375-4991-AE4E-1591FB80CA18</gtr:id><gtr:title>The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac7697bc61684200b8357127375ee26d"><gtr:id>ac7697bc61684200b8357127375ee26d</gtr:id><gtr:otherNames>Sherlock M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>56e11c5ea47616.61536148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F439D7-0DD1-47A0-A7BE-ECE3B9198A52</gtr:id><gtr:title>High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>5899cc5ff28a72.05872234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AB0BE9F-618E-4D9B-969D-87E711807A77</gtr:id><gtr:title>Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5d8ef8943d35a20e95fca492fd3713e"><gtr:id>b5d8ef8943d35a20e95fca492fd3713e</gtr:id><gtr:otherNames>Stewart PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>5899ccccb7c184.28270689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F8E4367-7897-4F1E-A476-0D2D7D8E22AA</gtr:id><gtr:title>Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3371bf5bd214349b10832ad888e2b5a7"><gtr:id>3371bf5bd214349b10832ad888e2b5a7</gtr:id><gtr:otherNames>Clayton RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>5899cccbaf37b7.12024305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBBE583F-2E7A-4F37-BB7A-FD4C9B57FE81</gtr:id><gtr:title>Dehydroepiandrosterone sulfate directly activates protein kinase C-beta to increase human neutrophil superoxide generation.</gtr:title><gtr:parentPublicationTitle>Molecular endocrinology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b09dc9515751f17ba71b746e43af0649"><gtr:id>b09dc9515751f17ba71b746e43af0649</gtr:id><gtr:otherNames>Radford DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0888-8809</gtr:issn><gtr:outcomeId>AN9sfNKAdWp</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801473</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>